Adding CAR T-Cell Therapy to the Electronic Medical Record

Video

Andrea Price, APN, discusses adding CAR T-cell therapy to the electronic medical record.

Andrea Price, APN, associate director for clinical research at Washington University School of Medicine, discusses adding CAR T-cell therapy to the electronic medical record (EMR).

While CAR T-cell therapy is not new to providers, the therapy is not yet integrated into the EMR system, explains Price. Adding CAR T-cell therapy to the EMRs requires a lot of collaboration with the EMR team to make sure it fits the workflows and special patient populations. These tools need to be designed from scratch, according to Price.

The priority regarding CAR T-cell therapy in EMR is creating nursing documentation for specialized orders for patients, says Price. Further implementation will require best practice advisories. The EMR has triggers that recognize patient traits to help providers drive decision making, which is the next step of adding CAR T-cell therapy to EMR. The challenge is avoiding overnotifying the providers or nurses and, instead, drilling down the specific patients within the EMR that need to be worked on, concludes Price.

Recent Videos
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
© 2025 MJH Life Sciences

All rights reserved.